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INTRODUCTION 
Cancer is a term used for diseases in which abnormal cells 
divide without control and are able to invade other tissues. 
Cancer cells can spread to other parts of the body through 
the blood and lymph systems
1
. The two main types of 
genes that are recognized as playing a role in cancer are 
oncogenes and tumor suppressor genes. Aberrant 
methylation is a widespread phenomenon in cancer and 
may be among the earliest changes to occur during 
oncogenesis. One of the major ro les of DNA methylation 
in mammals is thought to be in control of gene regulation. 
This is because methylation within gene regulatory regions 
such as promoters and enhancers generally suppresses their 
function
2
. Several lines of ev idence suggest that the methyl 
group in some cases directly interferes with the binding of 
transcription factors that activate transcription. In an 
alternative process, CpG-binding domain (MBD) proteins 
bind to the methyl group and subsequently to chromatin  
remodeling proteins (such as histone deacetylases) to 
silence the gene by making it transcriptionally unavailable. 
Genes that are methylated tend to be packaged more 
tightly, which causes them to be silenced. Genes that are 
not methylated tend to exhib it looser packaging, which 
allows their expression
3
. Mutations in certain tumour 
suppressor genes are most often thought of in association 
with their inactivation during cancer initiation or 
progression; epigenetic alterations such as DNA 
methylation appear to be tightly linked to the sequential 
non-reversible events of normal tissue differentiation and 
organogenesis
4
.  
Hence our objectives of the present study are to understand 
the lung cancer methylome which leads to identification of 
genes involved in causing lung cancers. Among the genes 
identified, tumor suppressor genes involved in lung cancer 
and their methylation frequencies are keyed out in 
different types of lung cancers. 
MATERIALS AND METHODS  
2.1. Retrieval  of Lung Cancer Genes Methylation 
Frequencies Information using PubMeth 
Pubmeth is an annotated and reviewed database of 
methylation in cancer. PubMeth can be queried using the 
web-interface at 
http://matrix.ugent.be/pubmeth/search.html in two ways, 
depending on the researcher's focus: Gene-related: in  
which cancer types (and subtypes) the genes of interest are 
reported to be methylated and Cancer-related: which genes 
are reported to be methylated in the cancer types/subtypes. 
The Cancer-centric query approach is opted for the 
retrieval of methylated genes involving in Lung cancer. 
This type of search is meant to get a quick overview of the
 
genes that are reported in the methylation context in the 
cancer
 
(sub) types of interest and in which frequency, to 
explore methylation
 
in the cancer types of interest
5
.
 
 
2.2. KEGG / Kyoto Encyclopedia of Genes & Genomes 
Pathway Maps 
The KEGG Pathway database is a collection of graphical 
diagrams (KEGG pathway maps) and associated text 
information (KEGG pathway entries) for metabolism, various 
other cellular processes, and human diseases
6
. The KEGG 
pathway map is a moleculalr interaction/reaction network 
diagram represented in terms of the KEGG Orthology (KO) 
groups, so that experimental evidence in specific organisms 
can be generalized to other organisms through genomic 
information. Each map is manually drawn with in-house 
software called KegSketch, which generates the KGML+ file7. 
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RES ULTS  
Table 1: Tumor Suppressor Genes identified in Lung Cancer  
 
 
Figure 1: Methylation Frequencies of Genes involved in Lung Cancer  
S.no Gene Description 
1 CDKN2A Cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4) 
2 RASSF1 Ras association (RalGDS/AF-6) domain family member 1  
3 DAPK1 Death-associated protein kinase 1 
4 RUNX3 Runt-related transcription factor 3 
5 APC Adenomatous polyposis coli 
6 CADM1 Cell adhesion molecule 1  
7 CDKN2B Cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4) 
8 DLC1 Deleted in liver cancer 1  
9 FHIT Fragile histidine triad gene 
10 PRKCDBP Protein kinase C, delta binding protein 
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Figure 2: Non-Small cell lung cancer  
Table 2: Methylation Frequencies of Tumor Suppressor Genes involved in Lung Cancer  
 
Methylation Frequencies 
 
NSCLC - Adenocarcinoma NSCLC - Squamous 
NSCLC – Large cell 
carcinoma 
SCLC 
0 – 20 % - 
CDKN2B 
RUNX3 
CADM1 
CDKN2A 
APC 
20 – 40 % 
CDKN2A; 2B 
RASSF1 
DAPK1 
RUNX3 
RASSF1 
DAPK1 
FHIT 
RASSF1 DAPK1 
40 – 60 % 
APC 
CADM1 
DLC1 
CDKN2A 
CADM1 
DLC1 
- - 
60 – 80 % - - 
CDKN2A 
RASSF1 
RUNX3 
RASSF1 
PRKCDBP 
80 – 100 % - - - - 
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Figure 3: Small cell lung cancer 
 
DISCUSS ION 
4.1. Identi fying the Tumor Suppressor Genes and their 
Methylation Frequencies 
By using PubMeth database, the genes which are found to 
be methylated in  various lung cancer cell lines are depicted 
in the figure 1. There are two different types of lung 
cancers i.e.., are NSCLC – Non-Small Cell Lung Cancer & 
SCLC – Small Cell Lung Cancer. The subtypes of NSCLC 
are: NSCLC-Adenocarcinoma, NSCLC-Squamous, and 
NSCLC-Large Cell Carcinoma.   Among those identified 
genes, the TSGs are recognized to know how many TSGs  
are involved in various types of lung cancers. Specific 
TSGs show different methylation status in respective types 
of lung cancers. Such kinds of methylation frequencies are 
also observed in other cancer types where the same TSGs  
may possess other methylation status.  
4.2. Methylation Frequencies of TS Gs in Lung Cancer  
In different types of lung cancers, it has been observed that 
no TSGs are likely having the same methylation 
frequencies / status. In each type of lung cancer different 
TSGs have different methylation status and these 
methylation statuses differ for various kinds of cancers 
also. The identified TSGs  are tabulated in the table 1 and 
their respective methylation frequencies are tabulated in 
table 2. The dark red coloration indicates the highest 
methylation frequency of the genes. Among the identified  
TSGs, the RASSF1 & CDKN2A TSGs are highly 
methylated and involved in both Non-Small Cell & Small 
Cell Lung Cancers.   
4.3. KEGG - NSCLC & S CLC Pathway Maps  
The identificat ion of TSGs in the cancer pathway maps 
gives an insight to the connectivity of other genes as well 
associative cellular mechanisms can be understood well. 
By the pathways, the ability to find the connectivity to 
other cellular pathways such as apoptosis, cell-cycle 
progression, etc can be graphically depicted. The pathway 
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maps provide focused information about the various genes 
associated, colligated and responsible for various cellu lar 
states. From the NSCLC pathway map (figure 2: NSCLC-
Non-S mall Cell Lung Cancer Pathway), it  can be 
depicted that the genes FHIT & RASSF1 are indirectly  
involved in controlling the various functions like reduced 
apoptosis, cell-cycle progression & proliferation through 
other key proteins like CyclinD1 & MST1. From the 
methylation frequencies analyses, the both TSGs are  
highly methylated which results them in uncontrolling the 
key functions of cell-cycle progression & proliferat ion. In  
the same manner, the SCLC pathway map (figure 3: 
SCLC-S mall Cell Lung Cancer Pathway), also provides 
informat ion regarding the other TSGs like Myc, RB, p53, 
PTEN along with the FHIT & CDKN2A genes which are 
methylated in both the SCLC & NSCLC. These TSGs play 
a crit ical functional ro le in inhib ition of apoptosis, 
degradation, tumor progression, proliferat ion and 
angiogenesis.  
CONCLUS ION 
By the PubMeth database studies, we can conclude that the 
minimum numbers of genes in lung cancer cell lines 
involved in methylation are 44 genes. Among these 44 
genes, 10 are identified as Tumor Suppressor Genes, and 
their detailed annotated information has been obtained 
through Genecards database. The 10 specific TSGs having 
different methylation frequencies have been observed. This 
indicates that methylation states are varied from one 
cancer to another type of cancer. The pathway maps focus 
the colligation of other genes and exploring differential 
gene connectivity and pathway conservation in identifying 
the novel ways to activate the tumor suppressor genes .  
ACKNOWLEGEMENTS  
We would like to thank GITAM University for providing 
Bioinformatics lab facility to carry out the research work. 
CONFLICT OF INTERES T - None  
 
REFERENCES 
1. Amajala Krishna Chaitanya, MTP. Mahalakshmi, I.  Bhaskar 
Reddy, Kaladhar DSVGK, Methylation profiling of tumor 
suppressor genes involved in various cancers and structural 
analysis of RASSF1 protein, IJCBPR, 2012, 2(1), 208-212. 
2. Susan J Clark and John Melki, DNA methylation and gene 
silencing in cancer: which is the guilty party?, Oncogene, 
2002, 21, 35, Pages 5380-5387. 
3. Bird A, Wolffe AP. Methylation-induced Repression: Belts, 
Braces and Chromatin. Cell. 1999. 99: 451-454. 
4. Garinis GA, Patrinos GP, Spanakis NE, Menounos PG, 
DNA hypermethylation: when tumour suppressor genes go 
silent. Hum Genet. 2002, Aug;111(2):115-27.  
5. Mate O, Leander VN, Tim DM, Gerben M , Sofie B and 
Wim VC, PubMeth: a cancer methylation database 
combining text-mining and expert annotation, Nucleic Acids  
Research, 2008, Vol. 36, D842–D846. 
6. Kanehisa M, Goto S, KEGG: Kyoto Encyclopedia of Genes 
and Genomes. Nucleic Acids Res., 2000, 28, 27-30. 
7. Kanehisa M, Goto S, Furumichi M, Tanabe M, Hirakawa M ; 
KEGG for representation and analysis of molecular 
networks involving diseases and drugs. Nucleic Acids Res.,  
2010, 38, D355-D360. 
8. Carlo S, Brueckner B, Tanja M, Helga S, Frank L, 
Functional Diversity of DNA Methyltransferase Inhibitors in 
Human Cancer Cell Lines, Cancer Res; 2006, 66: (5). March 
1, 2794-2800. 
9. Ivy FL. Tsui Raj Chari, Timon PH. Buys Wan L. Lam, 
Public Databases and Software for the Pathway Analysis of 
Cancer Genomes. Cancer Informatics, 2007, 3, 379–397. 
 
 
 
 
 
